Live Breaking News & Updates on Ambos Lawyers

Stay updated with breaking news from Ambos lawyers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Oxurion NV Business and Financial Update

Oxurion NV Business and Financial Update
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United-states , Brussels , Bruxelles-capitale , Belgium , Miami , Florida , New-york , Paris , France-general , France , Washington , Boston

Investegate |Oxurion NV Announcements | Oxurion NV: Oxurion NV Business and Financial Update – FY 2020


 
First patients dosed in Phase 2 study (‘KALAHARI’) evaluating multiple injections of THR-149, a potent plasma kallikrein inhibitor, for the treatment of DME. Part A data expected by mid-year
 
THR-687, a pan-RGD integrin antagonist, Phase 2 DME study planned to start by mid-year, following positive Phase 1 data released in 2020
 
The Company has strengthened the management team with the appointments of Tom Graney, CFA, based in Boston as CFO, Grace Chang M.D., PhD, based in LA as CMO, and Professor Alan Stitt, PhD as CSO.
 
At the end of December 2020, Oxurion had cash, cash equivalents & investments of €24.8 million, allowing the Company to execute on its business plans through the end of Q3 2021.  The Company is in advanced discussions with potential investors in order to increase its cash position. ....

United-states , Brussels , Bruxelles-capitale , Belgium , Miami , Florida , New-york , Paris , France-general , France , Washington , Boston

Oxurion NV Business and Financial Update – FY 2020


 
First patients dosed in Phase 2 study (‘KALAHARI’) evaluating multiple injections of THR-149, a potent plasma kallikrein inhibitor, for the treatment of DME. Part A data expected by mid-year
 
THR-687, a pan-RGD integrin antagonist, Phase 2 DME study planned to start by mid-year, following positive Phase 1 data released in 2020
 
The Company has strengthened the management team with the appointments of Tom Graney, CFA, based in Boston as CFO, Grace Chang M.D., PhD, based in LA as CMO, and Professor Alan Stitt, PhD as CSO.
 
At the end of December 2020, Oxurion had cash, cash equivalents & investments of €24.8 million, allowing the Company to execute on its business plans through the end of Q3 2021.  The Company is in advanced discussions with potential investors in order to increase its cash position. ....

United-states , Brussels , Bruxelles-capitale , Belgium , Miami , Florida , New-york , Paris , France-general , France , Washington , Boston

Oxurion NV Business and Financial Update – FY 2020

Oxurion NV Business and Financial Update – FY 2020
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

United-states , Brussels , Bruxelles-capitale , Belgium , Miami , Florida , New-york , Paris , France-general , France , Washington , Boston